ClinicalTrials.gg
RecruitingNCT06763575Updated Jan 8, 2025

Efficacy of Surgical Glove-Compression Therapy As a Prevention of Paclitaxel-Induced Peripheral Neuropathy

An interventional study of Surgical Glove-Compression Therapy and non-compressive plastic gloves in Paclitaxel-induced Peripheral Neuropathy, sponsored by Department of Medical Services Ministry of Public Health of Thailand. Recruiting at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-08.

Sponsored by Department of Medical Services Ministry of Public Health of Thailand · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this randomized controlled trial (RCT) is to compare the incidence of paclitaxel-induced grade 2 or higher sensory peripheral neuropathy, evaluated using the CTCAE version 5.0, between patients receiving surgical glove-compression therapy (SGCT) and those in the control group.

The main question is whether SGCT is effective in preventing paclitaxel-induced sensory peripheral neuropathy.

  • Intervention group: receive SGCT.
  • Control group: receive non-compressive plastic gloves.
Read the detailed description
  1. The study aims to test the hypothesis that SGCT is effective in preventing paclitaxel-induced peripheral neuropathy.
  2. The primary objective is to determine the incidence of grade 2 or higher paclitaxel-induced sensory peripheral neuropathy, assessed using the CTCAE version 5.0. Secondary objectives include evaluating the incidence of grade 2 or higher paclitaxel-induced motor peripheral neuropathy using CTCAE version 5.0, the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-NTX) score, the incidence of grade D or higher paclitaxel-induced sensory and motor peripheral neuropathy as measured by the Patient Neurotoxicity Questionnaire (PNQ), and the outcomes from the monofilament test.
  3. Sample size formula based on Bernard R. Fundamentals of biostatistics. 5th ed. Duxbery: Thomson learning; 2000. Enrollment of 36 patients.
  4. Randomization into two groups. The intervention arm will receive SGCT, while the control arm will receive non-compressive plastic gloves. The duration of treatment is 9 weeks.
  5. Enrollment and data monitoring are assessed by staff at the Oncology Unit, Rajavithi Hospital, and the data will be recorded in a computer-based information system.
  6. Data assessment will be conducted on weeks 0, 3, 6, and 9 during the chemotherapy treatment.
  7. Data analyzed by descriptive and inferential statistics.
02

Conditions studied

  • Paclitaxel-induced Peripheral Neuropathy

Keywords

  • Paclitaxel
  • Surgical Glove-Compression Therapy
  • Peripheral Neuropathy
03

In context

Peripheral Nervous System Diseases

476 studies on the registry are indexed under Peripheral Nervous System Diseases; 103 are open to participants now.

This study's planned enrollment of 36 is below the median of 57 across 359 interventional studies indexed under Peripheral Nervous System Diseases.

Browse Peripheral Nervous System Diseases studies →

Lead sponsor

Department of Medical Services Ministry of Public Health of Thailand is the lead sponsor of 39 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed Form
  • Age 18 years or older at the time of signing Informed Consent Form
  • Patients with any pathological diagnosis of solid tumor, such as breast cancer or lung cancer
  • Patients scheduled to be receiving intravenous paclitaxel or paclitaxel-based regimen every 3 weeks

Exclusion criteria

Exclusion Criteria:

  • Patients whose received chemotherapeutic agents that could cause neuropathy, e.g. taxane-based or platinum-based chemotherapy and anti-microtubule
  • History of neuropathy
  • History of carpal tunnel syndrome
  • History of allergic reactions to latex or gloves
  • Patients receiving treatments that may treat neuropathy, e.g. amitriptyline, gabapentin, Acetyl L-Carnitine and Ganglioside-monosialic acid, acupuncture, cryotherapy or exercise therapy
  • History of Raynaud phenomenon
  • History of wounds or large scars on hands
  • Pregnancy or breastfeeding
  • History of poorly controlled diabetes; >6.5
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Surgical Glove-Compression Therapy

    Patients wore double-layered surgical gloves, one size smaller than measured, covered by large cotton gloves on both hands, for 30 minutes before, during, and after chemotherapy.

    Device: Surgical Glove-Compression Therapy

  • Placebo comparator
    non-compressive plastic gloves

    Patients wore non-compressive plastic gloves, covered by large cotton gloves on both hands, for 30 minutes before, during, and after chemotherapy.

    Device: non-compressive plastic gloves

Interventions

  • DeviceSurgical Glove-Compression Therapy

    In the intervention group, patients wore double-layered surgical gloves, one size smaller than measured, covered by large cotton gloves on both hands, for 30 minutes before, during, and after chemotherapy.

  • Devicenon-compressive plastic gloves

    In the control group, patients wore non-compressive plastic gloves, covered by large cotton gloves on both hands, for 30 minutes before, during, and after chemotherapy.

06

What researchers measure

Primary outcomes

  1. Incidence of grade 2 or higher paclitaxel-induced sensory peripheral neuropathy using CTCAE version 5.0.

    The incidence of grade 2 or higher paclitaxel-induced sensory peripheral neuropathy was evaluated using the CTCAE version 5.0 for both the intervention and control groups.

    Time frame: 9 weeks

Secondary outcomes

  1. Incidence of grade 2 or higher paclitaxel-induced motor peripheral neuropathy using CTCAE versions 5.0

    The incidence of grade 2 or higher paclitaxel-induced motor peripheral neuropathy was evaluated using the CTCAE version 5.0 in both the intervention and the control groups.

    Time frame: 9 weeks

  2. FACT/GOG-NTX scores

    FACT/GOG-NTX scores in both the intervention and the control group.

    Time frame: 9 weeks

  3. Incidence of grade D or higher paclitaxel-induced sensory and motor peripheral neuropathy using the PNQ

    The incidence of grade D or higher paclitaxel-induced sensory and motor peripheral neuropathy using the PNQ in both the intervention and the control group.

    Time frame: 9 weeks

  4. Monofilament test results

    Monofilament test results in both the intervention and the control group.

    Time frame: 9 weeks

07

Study locations

1 of 1 sites recruiting
  • Rajavithi Hospital, Medical Oncology Unit
    Bangkok, 10400, Thailand
    Recruiting
    • Saowani Thantaviraya, M.D. · Contactsaowani.mook@gmail.com · +668-05564241
    • Sunatee Sa-nguansai, M.D. · Contactsunatee@hotmail.com · +66896949358
    • Kunlatida Maneenil, M.D. · Contact
    • Piyawan Tienchaiananda, M.D. · Contact
    • Songwit Payapwattanawong, M.D. · Contact
    • Saowani Thantaviraya, M.D. · Contact
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: December 2024 - December 2025

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Jan 2026, 12 months later.

Of 122 non-industry interventional studies with no phase under Peripheral Nervous System Diseases, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 12 months is below that.

Counting every sponsor, half of 132 studies reached it within 25 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2025
First posted
Jan 8, 2025
StartEst.
Jan 1, 2025
Primary completionEst.
Jan 1, 2026
CompletionEst.
Jun 1, 2026
Last update
Jan 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06763575
Lead sponsor
Department of Medical Services Ministry of Public Health of Thailand
Responsible party
Sponsor
First posted
Jan 8, 2025
Start date
Jan 1, 2025 (estimated)
Primary completion
Jan 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Jan 8, 2025

Study contacts

Saowani Thantaviraya, M.D.
Contact
saowani.mook@gmail.com
+66805564241
Sunatee Sa-nguansai, M.D.
Contact
sunatee@hotmail.com
+66896949358
Sunatee Sa-nguansai, M.D.
study director · Department of Medical Services Ministry of Public Health of Thailand
Saowani Thantaviraya, M.D.
principal investigator · Department of Medical Services Ministry of Public Health of Thailand
Kunlatida Maneenil, M.D.
principal investigator · Department of Medical Services Ministry of Public Health of Thailand
Piyawan Tienchaiananda, M.D.
principal investigator · Department of Medical Services Ministry of Public Health of Thailand
Songwit Payapwattanawong, M.D.
principal investigator · Department of Medical Services Ministry of Public Health of Thailand

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion